Outlook of IL-6 signaling blockade for COVID-19 pneumonia

Inflammation and Regeneration

Misato Hashizume¹ 

[1] Chugai Pharmaceutical Co., Ltd., 1-1 Nihonbashi-Muromachi 2-Chome, Chuo-ku, 103-8324, Tokyo, Japan;

关键词: Interleukin-6;    COVID-19 pneumonia;    Cytokine release syndrome;    Tocilizumab;    Sarilumab;    Siltuximab;   

DOI  :  10.1186/s41232-020-00134-7

来源: Springer

【 摘 要 】

In this review article, it is highlighted the implications of pleiotropic functions of interleukin-6 (IL-6) for one of the therapeutic options targeting for COVID-19. Moreover, it is discussed how real-world data and trials with IL-6 signaling blockade will be crucial in informing the development of new treatment for COVID-19 pneumonia.Given physiological roles of IL-6 in inflammatory conditions and the data from real world, IL-6 signal inhibitors, along with standard of care (SOC) treatment, might provide efficacy, offering the potential to treat COVID-19 in hospitalized populations more effectively than current SOC alone. Therefore, on-going and planned randomized placebo-controlled studies in combination with SOC and other therapeutics to assess safety and efficacy of IL-6 signal inhibitors in hospitalized patients with severe COVID-19 pneumonia will be warranted to address the high unmet need and burden of disease in this severely ill population.

【 授权许可】

CC BY